## You are cordially invited to participate...

## Understanding the Role of VASCEPA® (icosapent ethyl) as Add-on to Statins in Patients With Persistent High Triglyceride Levels (=200 to 500 mg/dL)

Guest Speaker:
Bonnie Seecharran, MD
Director of Cardiology
Middletown Medical
Middletown, New York

Cena 2000 50 Front Street Newburgh, NY 12550 (845) 561-7676

Wednesday, October 21, 2015 6:30 PM

Hosted by: Mario Mejorado (914) 475-8265

Please register at: <a href="https://amarin.phoenixgrpmeetings.com">https://amarin.phoenixgrpmeetings.com</a></a> Click on "Register for a Meeting." Enter code AMA-VAS-2103

Amarin policy limits attendance at meal functions to physicians, their supporting staff, pharmacists, and medical/pharmacy students. No other guests, including non-practicing spouses, are permitted to attend the program or consume the meal.

## **Indication and Limitations of Use**

VASCEPA® (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.

- The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
- The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.

## Important Safety Information for VASCEPA

- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
- Use with caution in patients with known hypersensitivity to fish and/or shellfish.
- The most common reported adverse reaction (incidence >2% and greater than placebo) was arthralgia.
- Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.
- In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.
- Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA.
- Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

See full Prescribing Information for more information on VASCEPA or go to www.vascepa.com.

